Anxiety in patients treated with hemodialysis
SD Cohen, D Cukor, PL Kimmel - Clinical Journal of the American …, 2016 - journals.lww.com
Anxiety is a common yet frequently overlooked psychiatric symptom in patients with ESRD
treated with hemodialysis (HD). Anxiety is characterized by disruptive feelings of uncertainty …
treated with hemodialysis (HD). Anxiety is characterized by disruptive feelings of uncertainty …
Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens
A change in pharmacokinetics can alter drug exposure and predispose the patient to either
over-or underdosing, potentially resulting in adverse drug reactions or therapeutic failure …
over-or underdosing, potentially resulting in adverse drug reactions or therapeutic failure …
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis
X Wang, G Tirucherai, TC Marbury… - The journal of …, 2016 - Wiley Online Library
An open‐label, parallel‐group, single‐dose study was conducted to assess the
pharmacokinetics, pharmacodynamics, and safety of apixaban in 8 subjects with end‐stage …
pharmacokinetics, pharmacodynamics, and safety of apixaban in 8 subjects with end‐stage …
Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms
Background Patients with kidney disease frequently experience adverse effects from
medication exposure, even when drugs are cleared by nonrenal pathways. Although many …
medication exposure, even when drugs are cleared by nonrenal pathways. Although many …
β-Blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial
Results Using the recovery clearance method, the dialytic clearance values for atenolol,
metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P< …
metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P< …
Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for …
F Alasmari, MS Alasmari, HM Muwainea… - Frontiers in …, 2023 - frontiersin.org
Introduction: Ceftriaxone is one of commonly prescribed beta-lactam antibiotics with several
label and off-label clinical indications. A high fraction of administered dose of ceftriaxone is …
label and off-label clinical indications. A high fraction of administered dose of ceftriaxone is …
Therapeutic drug monitoring of antibiotic drugs in patients receiving continuous renal replacement therapy or intermittent hemodialysis: a critical review
E Matusik, C Boidin, A Friggeri… - Therapeutic Drug …, 2022 - journals.lww.com
Purpose: Antibiotics are frequently used in patients receiving intermittent or continuous renal
replacement therapy (RRT). Continuous renal replacement may alter the pharmacokinetics …
replacement therapy (RRT). Continuous renal replacement may alter the pharmacokinetics …
A synopsis of clinical pharmacokinetic alterations in advanced CKD
TD Nolin - Seminars in dialysis, 2015 - Wiley Online Library
Unrecognized alterations in pharmacokinetics, which quantitatively describes the time
course of drug disposition in the body, may lead to clinically significant changes in systemic …
course of drug disposition in the body, may lead to clinically significant changes in systemic …
Design and conduct considerations for studies in patients with impaired renal function
P Ravenstijn, M Chetty… - Clinical and Translational …, 2021 - Wiley Online Library
An impaired renal function, including acute and chronic kidney disease and end‐stage renal
disease, can be the result of aging, certain disease conditions, the use of some medications …
disease, can be the result of aging, certain disease conditions, the use of some medications …
Chapter 2: indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney …
H Nishiyama, T Inoue, Y Koizumi, Y Kobayashi… - International Journal of …, 2023 - Springer
This comprehensive review discusses the dosing strategies of cancer treatment drugs for
patients with impaired kidney function, specifically those with chronic kidney disease (CKD) …
patients with impaired kidney function, specifically those with chronic kidney disease (CKD) …